<DOC>
	<DOC>NCT00559585</DOC>
	<brief_summary>The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an inadequate response to current methotrexate therapy.</brief_summary>
	<brief_title>Methotrexate-Inadequate Response Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects who are considered methotrexate inadequate responders 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint count) Subjects who failed one or multiple antitumor necrosis factor (TNF) therapies Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematous) Subjects with active vasculitis of a major organ system (except for subcutaneous rheumatoid nodules) Subjects with severe chronic or recurrent bacterial infections Subjects who have received treatment with rituximab An AntiTNF Failure Substudy was initiated (recruited separately from Main study) using the same treatment as the Main study in order to assess the immunogenicity and safety in the AntiTNF Failure population. The Substudy terminated due to low recruitment and participants were permitted to roll into the LT Open Label Period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>